We could not find any results for:
Make sure your spelling is correct or try broadening your search.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chroni... OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain. Show more
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.Conjunctival Staining improved as early as day 29 with a durable...
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.16 | 12.030075188 | 1.33 | 1.49 | 1.21 | 20775 | 1.34765374 | CS |
4 | -0.1 | -6.2893081761 | 1.59 | 1.59 | 1.21 | 23569 | 1.47993926 | CS |
12 | 0.1 | 7.19424460432 | 1.39 | 1.9 | 1.21 | 73055 | 1.53304611 | CS |
26 | -0.23 | -13.3720930233 | 1.72 | 2.12 | 1.19 | 108878 | 1.65471751 | CS |
52 | -0.03 | -1.97368421053 | 1.52 | 3.07 | 0.9201 | 147788 | 2.08146275 | CS |
156 | -3.01 | -66.8888888889 | 4.5 | 7 | 0.9201 | 176245 | 2.5172615 | CS |
260 | -3.01 | -66.8888888889 | 4.5 | 7 | 0.9201 | 176245 | 2.5172615 | CS |
Symbol | Price | Vol. |
---|---|---|
NVOSNovo Integrated Sciences Inc | $ 1.05 (132.82%) | 310.28M |
GWAVGreenwave Technology Solutions Inc | $ 0.0387 (-7.86%) | 305.13M |
FFIEFaraday Future Intelligent Electric Inc | $ 0.584899 (3.47%) | 223.84M |
SQQQProShares UltraPro Short QQQ | $ 10.02 (0.00%) | 161.89M |
CRKNCrown Electrokinetics Corporation | $ 0.0998 (-12.07%) | 155.13M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions